Immunogenic cell death

ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma

Retrieved on: 
Friday, June 10, 2022
Biotechnology, Pharmaceutical, Oncology, General Health, Health, FDA, Clinical Trials, Other Health, CR, Brentuximab vedotin, Lymphocytopenia, EDT, Company, HSCT, Diffuse large B-cell lymphoma, Biomedical sciences, Genmab, Control, Anemia, Humanitas University, ORR, LinkedIn, Progression-free survival, CEST, Forward-looking statement, Immunogenic cell death, European Hematology Association, Hypophosphatemia, Jaguar XK, BV, Hope, DOR, ADC, U.S. Securities and Exchange Commission, Camidanlumab tesirine, FDA, Hematopoietic stem cell transplantation, Patient, Therapy, Neutropenia, Cancer, PD-1, Technology, NYSE, Lymphatic system, Hodgkin lymphoma, Twitter, MD, Clinical trial, CD25, Department, PBD, Biologics license application, Thrombocytopenia, PFS, GBS, Enzyme, Hematology, Fine chemical, Pharmaceutical industry, San Francisco Bay Area, Camisole

ADC Therapeutics SA (NYSE: ADCT) announced today results from the ongoing pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami) in relapsed or refractory (r/r) Hodgkin lymphoma.

Key Points: 
  • ADC Therapeutics SA (NYSE: ADCT) announced today results from the ongoing pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami) in relapsed or refractory (r/r) Hodgkin lymphoma.
  • Cami has demonstrated consistently favorable response rates and durability in Hodgkin lymphoma patients who have relapsed, despite using the best available treatments.
  • Cami is being evaluated in a pivotal Phase 2 clinical trial in patients with relapsed or refractory Hodgkin lymphoma and a Phase 1b clinical trial as monotherapy and in combination with pembrolizumab in solid tumors.
  • Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors.

Provectus Biopharmaceuticals Presents Multiple Metabolic Complete Responders from PV-10® Treatment of Early-Stage Metastatic Uveal Melanoma Patients at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Wednesday, June 8, 2022
Acral lentiginous melanoma, Chairperson, Springfield Armory M1A, Caregiver, Immunotherapy, PET, Company, EASL, Survival, Hematology, MD Anderson Cancer Center, Legislation, Forward-looking statement, Immunogenic cell death, Security (finance), Metastasis, ASCO, Mum, U.S. Securities and Exchange Commission, NIH, Microbiology, Pennsylvania Railroad class M1, H. Lee Moffitt Cancer Center & Research Institute, M1C helmet, Epson HX-20, RBS, Ophthalmology, National, Patient, P.O, SEC, MCR, Clinical trial, Virology, Board, PET-CT, HX, Drug discovery, IL, Dermatology, RECIST, Safety, Vaccine, Medical imaging, Pharmaceutical industry

Translational research is underway at MDACC and Moffitt Cancer Center to elucidate the molecular basis for mCR responders vs non-responders.

Key Points: 
  • Translational research is underway at MDACC and Moffitt Cancer Center to elucidate the molecular basis for mCR responders vs non-responders.
  • We have gained valuable insights from this clinical trial that will be considered for future patient assessment and treatment protocols, as we continue to advance PV-10 for the treatment of metastatic uveal melanoma.
  • Mr. Rodrigues concluded, Metastatic uveal melanoma can be particularly threatening once it takes hold at metastatic sites around the body.
  • Information about the Companys clinical trials can be found at the National Institutes of Health (NIH) registry, www.clinicaltrials.gov .

Replimune Announces the Departure of Jason Rhodes from its Board of Directors

Retrieved on: 
Friday, June 3, 2022
Leadership, Goal, Coronavirus, Company, RPX, TME, Securities Exchange Act of 1934, Neoplasm, Securities Act of 1933, Forward-looking statement, Immunogenic cell death, Security (finance), U.S. Securities and Exchange Commission, Atlas Venture, Atlas, GLOBE, Pleasure, Tumor microenvironment, MOA, NASDAQ, Clinical trial, Board, Antigen, Safety, Pharmaceutical industry

Mr. Rhodes joined the Replimune Board in 2015, concurrent with Atlas Venture leading Replimunes Series A financing.

Key Points: 
  • Mr. Rhodes joined the Replimune Board in 2015, concurrent with Atlas Venture leading Replimunes Series A financing.
  • Mr. Rhodes has resigned to focus his efforts on his growing commitments at Atlas Venture, including the recent launch of its new fund, announced in March 2022.
  • We are grateful for Jasons service and I am joined by other directors and members of Replimunes executive team in wishing him well.
  • I am proud to have served on the Board since leading Replimunes Series A financing.

Replimune to Present at the Jefferies Healthcare Conference

Retrieved on: 
Thursday, June 2, 2022
Marriott Marquis, Conference, RPX, TME, Neoplasm, Immunogenic cell death, GLOBE, Tumor microenvironment, MOA, NASDAQ, Antigen, Washington Marriott Marquis, Safety, Mobile phone, Vaccine, Medical imaging

WOBURN, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its management team will present in a fireside chat at the Jefferies Healthcare Conference being held at the Marriott Marquis in New York, NY on Thursday, June 9, 2022 at 9:30 AM ET.

Key Points: 
  • WOBURN, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its management team will present in a fireside chat at the Jefferies Healthcare Conference being held at the Marriott Marquis in New York, NY on Thursday, June 9, 2022 at 9:30 AM ET.
  • Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies.
  • Replimunes proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response.
  • For more information, please visit www.replimune.com .

Agenus Advances Portfolio with 6 Clinical Collaborations

Retrieved on: 
Tuesday, May 31, 2022
Cancer, Multiple myeloma, Company, Immunotherapy, Immunogenic cell death, Infection, GMP, U.S. Securities and Exchange Commission, KRAS, Tumor microenvironment, Patient, Prostate, EP4, NASDAQ, PD-1, Immunosuppression, Neelam, Agenus, Therapy, Clinical trial, Mink, TCR, Partnership, Ovarian cancer, Lung, Security (finance), Tumor hypoxia, Prostaglandin, Immune system, Twitter, Oxford, Annual report, Risk, Evofosfamide, GLOBE, Pharmaceutical industry, Vaccine

These 6 collaborations span a range of Agenus clinical assets, including botensilimab (Fc-enhanced anti-CTLA-4), balstilimab (anti-PD-1), zalifrelimab (anti-CTLA-4), and QS-21 STIMULON.

Key Points: 
  • These 6 collaborations span a range of Agenus clinical assets, including botensilimab (Fc-enhanced anti-CTLA-4), balstilimab (anti-PD-1), zalifrelimab (anti-CTLA-4), and QS-21 STIMULON.
  • The combination studies are being sponsored and executed by our collaborators, with drug supply and scientific support provided by Agenus.
  • This strategy, enabled by in-house integrated manufacturing and scientific capabilities, positions Agenus to achieve the insights and advances needed to drive development on accelerated timelines.
  • Agenus new and ongoing clinical collaborations are supporting and enabling:
    Targovax to conduct a clinical trial combining botensilimab and balstilimab with ONCOS-102 (oncolytic virus) in patients with PD-1 relapsed/refractory melanoma.

Replimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Thursday, May 26, 2022
MOA, Herpes simplex virus, Immunogenic cell death, Neoplasm, U.S. Securities and Exchange Commission, Nasdaq, Tumor microenvironment, Progression-free survival, REPL, Patient, Goal, HSV, CSCC, TME, Review, Coronavirus, ORR, Clinical trial, Society, American Society of Clinical Oncology, RP1, CD40L, NSCLC, RP3, Securities Act of 1933, PFS, Securities Exchange Act of 1934, RP2, RPX, Bristol Myers Squibb, Toxicity, Antigen, Forward-looking statement, Safety, ASCO, Large-cell lung carcinoma, Drug Quality and Security Act, Nivolumab, Protein, Lymph, CR, Security (finance), Melanoma, GLOBE, Pharmaceutical industry, Vaccine, Sanofi, Regeneron Pharmaceuticals

WOBURN, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 3 to June 7, 2022.

Key Points: 
  • WOBURN, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 3 to June 7, 2022.
  • The clinical trial is enrolling 180 patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) who are nave to anti-PD-1 therapy.
  • The study is being conducted under a clinical trial collaboration agreement with Regeneron in which the costs of the trial are shared and full commercial rights retained by Replimune.
  • There are 4 tumor specific cohorts currently enrolling in this clinical trial including a 125-patient cohort in anti-PD-1 failed cutaneous melanoma.

Candel Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Retrieved on: 
Wednesday, May 18, 2022
Form, Company, Immunogenic cell death, Private Securities Litigation Reform Act, CADL, Content discovery platform, Nasdaq, Doctor of Philosophy, Patient, HSV, Therapy, Conference, Virus, Technology, SEC, Cancer, MD, GLOBE, Online shopping, Vaccine, Candel, Fellow of the Academy of Medical Sciences

NEEDHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present an overview of the company at H.C. Wainwrights upcoming Annual Global Investment Conference.

Key Points: 
  • NEEDHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present an overview of the company at H.C. Wainwrights upcoming Annual Global Investment Conference.
  • To access the webcast recording of the company presentation, please visit the Candel Therapeutics website at https://ir.candeltx.com/news-and-events/events-and-presentations.
  • CAN-2409 is the lead product candidatefrom the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform.
  • The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

CG Oncology Presents Additional Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

Retrieved on: 
Monday, May 16, 2022
Biotechnology, Health, Oncology, Clinical Trials, MSD, American Association for Cancer Research, Hypothyroidism, Immunotherapy, Immunogenic cell death, Annual general meeting, Chills, Bladder cancer, American Urological Association, Urine, Hematuria, GM, Patient, Merck & Co., AACR, Session, Nocturia, Merck Sharp & Dohme Federal Credit Union, Pembrolizumab, Hyperglycemia, Antigen, BCG, AUA, Safety, GM-CSF, NMIBC, Rupture, American Association, Nivolumab, Urinary bladder, CR, Pharmaceutical industry, Dysuria, Merck, Fatigue

91% of patients evaluable for efficacy (n=20/22) have achieved complete response (CR) at the initial 3-month timepoint.

Key Points: 
  • 91% of patients evaluable for efficacy (n=20/22) have achieved complete response (CR) at the initial 3-month timepoint.
  • CG Oncology is a clinical-stage biotechnology company focused on developing the next evolution of oncolytic immunotherapy for patients with advanced cancer.
  • Other types of bladder cancer are being evaluated with CG0070 in combination with OPDIVO (nivolumab), and additional indications in other solid tumors are being pursued with CG0070 in combination with other immune checkpoint inhibitors.
  • At CG Oncology, we aim to take the next evolutionary step in delivering innovative cancer care to millions of patients in need worldwide.

Promontory Therapeutics Appoints Johan Baeck, MD, as Executive Vice President and Chief Medical Officer

Retrieved on: 
Monday, May 16, 2022
Senior, Medical Affairs Bureau, Immunogenic cell death, VP, Damage-associated molecular pattern, Tumor microenvironment, Prostate, Merck Serono, NCI, Thymoma, Therapy, Novartis, Trial of the century, Orphan drug, Research, Immunocore, B cell, Promontory, Heart, ICD, Medical degree, Abbott Laboratories, Merck Group, Pharmaceutical industry, Medical imaging, MD

NEW YORK, May 16, 2022 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, today announced the appointment of Johan Baeck, MD, as Executive Vice President and Chief Medical Officer. Dr. Baeck joins Promontory Therapeutics from Jounce Therapeutics where he served as Senior Vice President, Clinical Development and Medical Affairs.

Key Points: 
  • NEW YORK, May 16, 2022 /PRNewswire/ -- Promontory Therapeutics Inc. , a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, todayannounced the appointment of Johan Baeck, MD, as Executive Vice President and Chief Medical Officer.
  • Dr. Baeck joins Promontory Therapeutics from Jounce Therapeutics where he served as Senior Vice President, Clinical Development and Medical Affairs.
  • Joseph F. O'Donnell, MD, who previously served as Chief Medical Officer, will remain with Promontory Therapeutics and assume the role of Senior Medical Director focusing on patient eligibility, enrollment and clinical case management.
  • His extensive clinical development and medical affairs experience with both large pharmaceutical and smaller biotech companies complements our growth strategy," said Promontory President and Chief Executive Officer Robert Fallon.

ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress

Retrieved on: 
Thursday, May 12, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, Department, Lymphoma, DNA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Company, Lymphoid leukemia, Humanitas University, Immunogenic cell death, Hospital, Food, Enzyme, PBD, MD, Distortion, 2021 Essex County Council election, Patient, Biomedical sciences, DNA repair, Camidanlumab tesirine, View, ADC, Hodgkin lymphoma, Therapy, Diffuse large B-cell lymphoma, Hematology, Genmab, Induced cell cycle arrest, Control, Lymphatic system, Adult, BLA, Relapse, FDA, Genetics, B-cell lymphoma, DLBCL, CHL, NYSE, European Hematology Association, Technology, LinkedIn, Twitter, Cancer, CD25, Jaguar XK, Pharmaceutical industry, Vaccine, Fine chemical, Camisole, Safety, San Francisco Bay Area

As we advance Cami toward a potential BLA submission, we look forward to sharing these data with the hematology community at EHA2022.

Key Points: 
  • As we advance Cami toward a potential BLA submission, we look forward to sharing these data with the hematology community at EHA2022.
  • Once bound to a CD25-expressing cell, Cami is internalized into the cell where enzymes release the PBD-based payload, killing the cell.
  • In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.